home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2868.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2868
DOCN M94A2868
TI The interim safety results and pharmacokinetics of a combination of
R89439 and zidovudine therapy in HIV-infection.
DT 9412
AU Colebunders R; Vandenbruaene M; Delescluse J; Vander Endt D; De Cree J;
De Brabander M; Peeters M; Van den Broeck R; Stoffels P; Tropical
Institute of Antwerp, Belgium.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):206 (abstract no. PB0252). Unique
Identifier : AIDSLINE ICA10/94369707
AB R89439 (loviride) is the most potent product of the alpha-APA series (A
group of Non Nucleoside Reverse Transcriptase Inhibitors) with an IC50
of 1.7 ng/ml and good oral bioavailability (Cp at 8h = 130 ng/ml).
OBJECTIVES: The objectives of the present trial were to document the
possible pharmacokinetic interactions between loviride on zidovudine and
to assess the safety of the combination therapy of loviride 50 mg or 100
mg t.i.d. with zidovudine. METHODS: 18 patients were randomized in three
groups of 6 patients in a double blind, double dummy placebo-controlled
clinical trial. Patients received either loviride 100 mg t.i.d., 50 mg
t.i.d. or placebo together with zidovudine. HIV1-positive patients with
CD4 > 50 and < 350 CELLS/mm3 were eligible if they had taken zidovudine
since more than 18 months. RESULTS: It was concluded that the
pharmacokinetics of zidovudine were not affected by cotreatment with
loviride 50 and 100 mg t.i.d. Sofar the codes have not been broken for
the interim safety analysis. The incidence of adverse events was not
significantly different between the three treatment groups, except for
diarrhea which was only reported in one group. No clinically important
laboratory changes were noted except for increased liver enzymes in one
group, which progressively normalised after discontinuation of
treatment. CONCLUSION: Adverse experiences although numerous were mostly
mild to moderate. The complete safety and efficacy results will be
reported at the conference.
DE Acetamides/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
PHARMACOKINETICS/*THERAPEUTIC USE Acetophenones/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/ PHARMACOKINETICS/*THERAPEUTIC USE Antiviral
Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
PHARMACOKINETICS/*THERAPEUTIC USE Double-Blind Method Drug
Interactions Human HIV Infections/*DRUG THERAPY Reverse
Transcriptase/*ANTAGONISTS & INHIB Safety Treatment Outcome
Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
PHARMACOKINETICS/*THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT
RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).